Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

Blumenthal Nordrehaug Bhowmik De Blouw LLP, Files Lawsuit, Against Redwood Toxicology Laboratory, Inc., for Allegedly Failing to Reimburse Employees for Expenses


Law Office of Blumenthal Nordrehaug Bhowmik De Blouw LLP

For more information about the class action lawsuit against Redwood Toxicology Laboratory, call (800) 568-8020 to speak to an experienced California employment attorney today.

The San Francisco employment law attorneys, at Blumenthal Nordrehaug Bhowmik De Blouw LLP, filed a class action lawsuit against Redwood Toxicology Laboratory, Inc. alleging the company violated the California Labor Code. The lawsuit against Redwood Toxicology Laboratory is currently pending in the Sonoma County Superior Court, Case No. SCV-271680. To read a copy of the Complaint, please click here.

According to the lawsuit filed, Redwood Toxicology Laboratory, Inc. allegedly (a) failed to pay minimum wages, (b) failed to pay overtime wages, (c) failed to provide legally required meal and rest periods, (d) failed to provide accurate itemized wage statements, (e) failed to reimburse employees for required expenses, (f) failed to pay sick pay wages, and (g) failed to provide wages when due, all in violation of the applicable Labor Code sections listed in California Labor Code Sections §§ 201-204, 226, 226.7, 233, 246, 510, 512, 1194, 1197, 1197.1, 2802, and the applicable Wage Order(s), and thereby gives rise to civil penalties as a result of such alleged conduct.

The complaint alleges Redwood Toxicology Laboratory, Inc. failed to pay employees for all the time they were under the employer’s control. This, allegedly, includes the time Plaintiff and other California Class Members had to submit to mandatory COVID-19 questionnaires and temperature checks prior to clocking in for the day. To the extent that the time worked off, the clock did not qualify for overtime premium payment, Defendant allegedly failed to pay minimum and overtime wages for the time worked off-the-clock.

For more information about the class action lawsuit against Redwood Toxicology Laboratory, Inc., call (800) 568-8020 to speak to an experienced California employment attorney today.

Blumenthal Nordrehaug Bhowmik De Blouw LLP is a labor law firm with law offices located in San Diego County, Riverside County, Los Angeles County, Sacramento County, Santa Clara County, Orange County, and San Francisco County. The firm has a statewide practice of representing employees on a contingency basis for violations involving unpaid wages, overtime pay, discrimination, harassment, wrongful termination, and other types of illegal workplace conduct.

***THIS IS AN ATTORNEY ADVERTISEMENT***

Share article on social media or email:

Tergus Pharma Announces Michael Kane as Chief Executive Officer


Tergus Pharma, a commercial scale Contract Development and Manufacturing Organization (CDMO) of semi-solid and liquid dosage forms, announced today that Michael Kane has been appointed as the Company’s new Chief Executive Officer. Dr. Vijendra Nalamothu, Tergus’ founder who has served as Chairman & CEO since 2012, will assume the role of Executive Chairman & Chief Scientific Officer.

“We are thrilled to welcome Michael Kane as the new CEO of Tergus and I am confident that he will continue the scientific excellence and transformation at Tergus. As Executive Chairman I will be able to focus more on our growth strategy and related scientific efforts, while Kane will be empowered as CEO to manage overall corporate operations. I look forward to working closely with Michael in my role as Executive Chairman & Chief Scientific Officer to help write Tergus Pharma’s next chapter,” said Dr. Nalamothu.

Mr. Kane joins Tergus with over thirty years of manufacturing experience and commercial scale operations. Prior to joining Tergus, Mr. Kane was in company leadership roles as the CEO and COO on middle market pharmaceutical and healthcare product companies that developed and manufactured topical, solid, soft gel, oral liquid and powder dosage forms across branded Rx, generic, OTC and medical nutrition segments. He was also an Operating Partner and board director at Blue Point Capital Partners, a private equity firm based in Cleveland, Ohio. Mr. Kane’s prior experience also includes operational leadership positions at Novartis and Abbott Laboratories.

Mr. Kane stated, “I am pleased to join the Tergus management team at an important inflection point in the company history. I was attracted to the role at Tergus because of their deep scientific expertise, their excellent facility, and impressive roster of clients that have developed over the past ten years. It is clear the future is very bright for the organization, and I look forward to working with employees and customers to build a leading topical CDMO.”

About Tergus Pharma

Tergus is an end-to-end contract service provider for topical pharmaceutical products supporting early phase research and formulation, drug development, testing, and both clinical and commercial manufacturing at our new 100,000 sq. ft. state-of-the-art facility in Durham, North Carolina. Tergus has developed a reputation for delivering quality results to clients for topical semi-solids and liquids for skin, otic, nasal, ophthalmic, vaginal, and rectal routes of administration. With industry-recognized leadership and expertise in method development, such as IVRT and IVPT, for topical pharmaceuticals, Tergus also provides clients with peace of mind and helps them to de-risk their product development, tech transfer, and manufacturing activities. Exclusively focused on topical development and manufacturing, Tergus brings the scientific expertise that helps our clients achieve the right balance of scientific knowhow, speed of results, and quality. For more information, please visit https://www.TergusPharma.com/

Share article on social media or email:

Martin Hernandez Law Office Now Open On Kennedy In Tampa.


Martin J. Hernandez, Esq.

Tampa Accident Injury Attorney Martin J. Hernandez, Esq.

“The only thing that has changed is the name, phone number and now we completely focus on personal injury law,” said Hernandez. “I have been able to retain all of my experienced and compassionate staff and will be able to make this transition seamlessly.”

Attorney Martin J. Hernandez announces his new law firm. The new firm, at the same location, has the same dedicated paralegals, case managers, and support staff and is completely dedicated to serving personal injury victims in the Tampa Bay Area.

Hernandez has been practicing law since 2001 and is one of the few attorneys in Florida to have tried over 100 jury trials. With a focus on auto accidents and other negligence claims, his career started by joining the Office of State Attorney for the Thirteenth Judicial District in Hillsborough County as an Assistant State Attorney. He was then promoted to the position of a lead trial attorney in the narcotics division and tried numerous high-profile, complicated cases. He went into private practice in 2004 to further help those in need and after an 18-year successful partnership, Martin decided to pursue a practice in helping victims.

“The only thing that has changed is the name, and phone number and now we completely focus on personal injury law,” said Hernandez. “I have been able to retain all of my experienced and compassionate staff and will be able to make this transition seamlessly.”

Hernandez primarily handles cases that arise from auto accidents, motorcycle accidents, premises liability, slips or trips, falls, and negligent security. In addition, he is currently an Eagle member of the Florida Justice Association, regarded as the premier trial lawyer organization for the State of Florida; Tampa Bay Trial Lawyers Association; Latin Chamber of Commerce, Ybor City Rotary Club; Trustee for Boys and Girls Club; Knights of Sant’Yago; and involved in the Boy Scouts of America (Eagle Scout, former Cubmaster, and currently an Assistant Scoutmaster).

###

About Martin Hernandez Law Office. The Office is located at 3002 W. Kennedy Blvd., in Tampa, Florida. Mr. Hernandez also has achieved numerous verdicts, judgments, and settlements well above the defendant’s policy limits. In one case he handled, the insurance company paid $1.2 million to his client when the defendant’s policy limit was only $25,000. Additionally, he settled many other cases that resolved for 10 to 50 times the policy limits of the defendant. Very few attorneys have the knowledge, skill, or fortitude to try to resolve a case for more than the policy limits.

Share article on social media or email:

XP Health CEO and Co-Founder Antonio Moraes Selected for BenefitsPRO Luminaries Class of 2022


News Image

I co-founded XP Health with a mission to democratize access to high-quality, yet affordable experiences in vision care. This award is a milestone that sheds a light on our tremendous growth and progress as an organization.

Antonio Moraes, CEO and Co-founder of XP Health, the company developing a digital-first vision benefits platform, has been named to BenefitsPRO Luminaries Class of 2022 in the category of Fresh Faces – Humanizing Benefits. This professional recognition program celebrates top benefits professionals and organizations that strive to transform and humanize the benefits business and set a bright example within the industry.

Honorees are selected by a panel of industry experts based on how well they stated and achieved goals with regards to the nomination category; how impactful their work has been; how dedicated the nominee has been to furthering modernization and humanization in the insurance business; and the nominee’s commitment to the highest ethical standards as well as dedication to service and Excellence.

“This year’s honorees exemplify how leading benefits professionals are moving their industries toward a brighter future and producing meaningful results in the areas that matter most to employers, employees and the future of the benefits and health care landscape,​” says BenefitsPRO Editor In Chief Paul Wilson. “Our team is excited to recognize these industry thought leaders and innovators as part of our inaugural LUMINARIES program.”

XP Health is the world’s first AI-powered vision benefits platform covering employees and their families. Its seamless online vision platform handles everything from in-person eye exams to buying affordable and brand name eyewear online, offering high-quality vision care easily with no co-pays, claims, or hassles. Moraes is a world-renowned investor and with XP Health, he is reshaping the often confusing, expensive, and frustrating experience of vision care– an industry that has seen minimal innovation over the past 20+ years.

“I am thrilled to be named as an honoree in the BenefitsPRO Luminaries Class of 2022. It’s an honor to be recognized alongside key industry players that are pushing us towards a more humanized, impactful insurance industry,” says Moraes. “I co-founded XP Health with a mission to democratize access to high-quality, yet affordable experiences in vision care. This award is a milestone that sheds a light on our tremendous growth and progress as an organization.”

About XP Health

XP Health democratizes access to high-quality, delightful experiences in vision care that double coverage and reduce costs by half. It is the first modern vision platform focused on eye care and eyewear that can be used to enhance or replace existing vision plans, and uses artificial intelligence, augmented reality, and customer-centric design to create a stellar member experience. XP Health was named to the 2021 Fast Company list of the World’s Most Innovative Companies and over the past year has expanded from 30 to 1500+ customers, including Docusign, Navistar, Chegg, Sequoia Consulting and strategic partner Guardian Life Insurance. To learn more visit xphealth.co.

Share article on social media or email:

InquisitHealth Expands to Help Scale Evidence-based Breast Cancer Peer Program


News Image

We have already demonstrated the efficacy of this approach. This trial is focused on how to integrate a web-based platform like InquisitHealth to help support scalability and dissemination. Dr. Bernardine Pinto, Ph.D.

InquisitHealth today announced the expansion of its Peer engagement technology platform, Mentor1to1™, to deliver a validated physical activity program for breast cancer survivors.

This technology-enabled program will be evaluated as part of an NIH-funded R01 randomized clinical trial, ‘Moving Forward Together,’ in collaboration with leading researchers and clinicians at the University of South Carolina, the University of Colorado, and Brown University.

There is a large body of evidence on the benefits of aerobic exercise to alleviate the sequelae of cancer treatments.

Therefore, the American College of Sports Medicine recommends regular exercise for cancer survivors, but as many as 46%-76% of survivors do not exercise at recommended levels.

In a prior randomized controlled trial led by Dr. Bernardine Pinto, Ph.D., the Primary Investigator in this trial, Peers were trained to deliver a 12-week home-based physical activity intervention to breast cancer survivors. The Peers, who were also breast cancer survivors, delivered 12 weekly counseling phone calls 1-on-1. This program significantly increased survivors’ moderate-to-vigorous physical activity (MVPA) as measured by an accelerometer from 13 minutes/week at baseline to 70 minutes/week at the end of the program. The control group, in comparison, increased MVPA from 14 minutes/week to just 17 minutes/week (p<0.05).

“We have already demonstrated the efficacy of this approach,” shared Dr. Pinto. “This trial is focused on how to integrate a web-based platform like InquisitHealth to help support scalability and dissemination.”

The scaling up of this proven intervention will require having a feasible, lower-cost means of managing program delivery, tracking fidelity, and delivering consistent results. By adapting InquisitHealth’s platform to support intervention delivery, the goal is to streamline key resource-intensive processes, including (a) Peer management; (b) matching survivors with an appropriate Peer based on multiple important criteria; (c) 1-on-1 HIPAA-compliant program delivery providing structure as well as personalization; and lastly, (d) tools to assure intervention fidelity and improvement in clinical outcomes.

“There are many compelling use cases for Peers. This is an opportunity to translate another proven approach from bench to bedside,” shared Dr. Ashwin Patel, M.D. Ph.D., Co-Investigator on the trial and CEO of InquisitHealth. “So many great concepts live in academia, and only in academia. We are excited to help bridge the gap.”

InquisitHealth provides health plans and health systems with a remote, tech-enabled workforce of Peers (community health workers paired with patients based on their shared cultural background, clinical condition, and lived experience). This Peer workforce helps engage patients, address their social needs, and improve their chronic disease management. These interventions are structured, highly personalized, and delivered 1-on-1 via InquisitHealth’s Mentor1to1™ technology platform for conditions like diabetes, pre-diabetes, hypertension, and asthma.

For this trial, the recruitment of both Peers and participants is being actively supported by the MemorialCare Todd Cancer Institute, Cancer Hope Network, Pink Lemonade Project, and the Delaware Breast Cancer Coalition.

“This is an important opportunity to actively connect our peer support work to direct improvements in clinical outcomes,” said Cynthia Gutierrez Bernstein, Executive Director of the Cancer Hope Network. “We are excited to participate in this trial.”

The 12-week intervention will be provided on a rolling basis. Recruitment of both Peers and participants has begun. Once the evaluation is complete, the results will be published in a peer-reviewed publication.

This is a unique collaboration among researchers, healthcare systems, cancer support organizations, and patients to leverage a proven technology platform to expand a proven breast cancer peer support program so that, eventually, many more patients can benefit.

This NIH-funded randomized clinical trial will pave the way for the dissemination of this important evidence-based breast cancer support program.

About InquisitHealth

InquisitHealth helps health systems and health plans leverage a remote community health workforce of Peers to engage patients with empathy. Peers are matched 1-on-1 with struggling patients based on their shared cultural background, clinical condition, and lived experience. Peers leverage shared empathy to engage, understand and help struggling patients overcome their SDoH barriers and better manage their chronic conditions. Highly personalized 1-on-1 engagement is tech-guided and optimized to deliver a better healthcare experience and improve clinical outcomes. This tech platform, Mentor1to1™, is currently utilized in multiple NIH- and PCORI-funded research programs to both create and evaluate tech-enabled expansions of Peer programs to serve new patient populations.

→ Learn more about our work @ http://www.inquisithealth.com

Share article on social media or email:

Deep Bio Selected as ‘Korea AI Startup 100’ for Two Consecutive Years


with our innovative deep learning technology, we will strive to lead the digitalization of medical care

Deep Bio, a pioneer in medical AI for digital pathology and cancer diagnostics support software, announced that it has been selected as one of the promising AI startups in the ‘Korea AI Startup 100’ list for the second time in a row.

‘Korea AI Startup 100’, an annual accelerator project cohosted by the Korea Economic Daily and AI One Team, an Industry-University-Research Council, discovers promising Korean AI startups. The project aims to support companies to strengthen their market presence and build their capability, thus enhancing national AI competitiveness in the global market as well as boosting the establishment of the startup ecosystem.

To choose the most notable 100 startups, a committee made up of AI experts evaluated candidates based on criteria that the Korea Advanced Institute of Science and Technology (KAIST) and KT Economics & Management Research Institute developed. The applicants were assessed on both quantitative factors such as market growth potential, corporate value, competitiveness in the AI technology space, and qualitative aspects including corporate sustainability.

After three rounds of evaluation, Deep Bio was selected as one of the finalists of the Korea AI Startup 100 in the healthcare industry. “It is a great honor to be designated as a promising startup that represents Korea. This opportunity once again becomes motivation for our company to advance our AI capability that can contribute to the society,” said Sun Woo Kim, the CEO of Deep Bio. He also added, “with our innovative deep learning technology, we will strive to lead the digitalization of medical care.”

Deep Bio, which initiated AI-based pathology image analysis and cancer diagnosis research in Korea, is leading the digital transformation in pathology with Korea’s first approved AI-based cancer diagnostic support software DeepDx®-Prostate and AI-based prostate cancer severity-grading software DeepDx®-Prostate Pro. More importantly, the company plans to execute l purchase agreements with five Korean hospitals for DeepDx®-Prostate Pro, through the Public Procurement Marketplace program run by the Korean Public Procurement Service (PPS).

Deep Bio also continues to build its global presence through overseas partnerships with digital pathology platform providers in the US, Europe, and India, as well as conduct research cooperation with Stanford Medical School, Harvard Dana-Farber Cancer Institute, and other top research institutions in the US. The company also has been presenting its novel research results in prestigious science and technology journals including the Cancers Journal, npj Digital Medicine, among others.

About Deep Bio

Deep Bio Inc. is an AI healthcare company with in-house expertise in deep learning and cancer pathology. Our vision is to radically improve efficiency and accuracy of pathologic cancer diagnosis and prognosis, by equipping pathologists with deep learning-based IVD SaMDs (In Vitro Diagnostics Software as a Medical Device), for optimal cancer treatment decisions. To learn more, visit http://www.deepbio.co.kr.

DeepDx® Prostate is a clinically-validated AI for prostate core needle biopsy tissue image analysis. Whole-slide images (WSIs) of H&E-stained biopsy tissue specimens are analyzed for prostate cancer, Gleason scores and grade groups. Extensively tested at 4 US CLIA labs (700k+ cores from 2019 to 2021), DeepDx® Prostate can alleviate the shortage of pathologists and the resultant increase in workload, while reducing diagnostic subjectivity and variability. To learn more, visit http://www.deepbio.co.kr

Share article on social media or email:

Explore how Breakthroughs in Biology are Improving Treatment of Preeclampsia


News Image

On an upcoming segment of Advancements with Ted Danson, audiences will learn about the latest developments in novel siRNA therapies for treatment of preeclampsia.

The show will educate about preeclampsia; a pregnancy complication characterized clinically by high maternal blood pressure and signs of damage to other organ systems, which afflicts roughly 10 million patients worldwide and accounts for roughly 80,000 maternal and more than 500,00 fetal deaths.

The segment will explore how preeclampsia affects developed and developing countries – and how it disproportionately affects women who are the youngest, the oldest, and the poorest. With a look at Comanche Biopharma –a preclinical biopharmaceutical company developing a novel siRNA therapy for the treatment of preeclampsia– viewers will learn how its preclinical therapy for the treatment of preeclampsia aims to lower the risks of pregnancy and prematurity worldwide by safely sustaining natural pregnancy.

“After 30 years of scientific research, we have brought together three achievements. We’ve unlocked a mechanistic basis for modifying the disease, and in combination with advancements in oligonucleotide chemistry, we can now fully leverage the remarkable discovery of RNA interference to treat this terrible condition,” said Dr. Scott Johnson, CEO of Comanche Biopharma.

The show will explore Comanche’s approach to treating sFlt1 mediated hypertension disorders of pregnancy via its siRNA molecules, which is capable of specifically and durably silencing the sFlt1 gene in the placenta, thereby downregulating production of a protein that plays a key role in the development of preeclampsia.

“These grave outcomes are often more severe in low- and middle-income areas, where healthcare resources can be scarce. Comanche envisions a world where all pregnant women have access to safe and effective therapies that are evidence-based, cost-effective, and sustainable,” said Richard Lubin, senior producer for the Advancements series. “We look forward to spreading this information and message.”

About Comanche Biopharma:

Comanche is a preclinical biopharmaceutical company developing a novel siRNA therapy for the treatment of preeclampsia. Its purpose is to lower the risks of pregnancy and prematurity worldwide by safely sustaining natural pregnancy. Founded by an experienced group of physicians, researchers, biologists, chemists, ethicists, and pharmaceutical professionals who recognize the challenge of drug development for mothers and babies but are committed to the women and their families who have been disproportionately underserved by the drug industry for decades. Comanche believes every mother has the right to choose evidence-based therapies that have been appropriately studied to determine their risk-benefit and solve life-threatening conditions of pregnancy.

For more information, visit: http://www.comanchebiopharma.com.

About Advancements and DMG Productions:

Advancements is an information-based educational television series that explores recent developments taking place across several industries and economies. Shining a light on important issues and topics impacting society today, the series features the cutting-edge improvements, state-of-the-art technologies, and innovative solutions responsible for shaping, molding, and transforming our world.

Backed by experts in various fields, DMG Productions is dedicated to education and advancement, and to consistently producing commercial-free, educational programming for viewers and networks.

For more information, please visit http://www.AdvancementsTV.com or call 866-496-4065.

Share article on social media or email:

Christie CounterAct UR10 added to line of UVC disinfection fixtures


Image of Christie CounterAct UR10 overlaying an image of 5 people sitting around a table having a business meeting.

Christie CounterAct UR10 added to line of UVC disinfection fixtures

The high-power upper room ultra-violet germicidal irradiation (UVGI) disinfection performance of UR10, combined with visible light capabilities to light your space, allows businesses to replace existing commercial light fixtures as a cost-effective solution.

As we continue to see relaxed COVID-19 restrictions — leaving the onus of safety in the hands of business operators, owners and facilities managers — global visual technologies company Christie® is pleased to introduce its newest CE- and UL- certified commercial UVC-LED disinfection light fixture for occupied, indoor spaces. Christie CounterAct™ UR10 with UVC-LED and patented Care222® far-UVC – plus visible light, in a single unit, is recommended for commercial offices, government facilities, schools, transit hubs, retail shops, medical buildings — for enhanced and safe airborne and surface disinfection wherever people gather indoors, in public places.

CounterAct UR10 builds on the release of the CA20, Christie’s first far-UVC disinfection fixture, and the desire among global business and government leaders to increase confidence and improve wellbeing in our indoor spaces, such as meeting rooms, classrooms, and other places people gather. Combining filtered Care222® far-UVC light with upper room high-power mercury-free UVC-LED, CounterAct UR10 is an evolution in technology for treating both surfaces and air in occupied indoor spaces.

The new reality is that on average we’re seeing a pandemic arise every four years since the year 20001. This trend indicates the 2023 common cold, flu season and the next pandemic are right around the corner. This is why the U.S. government is committing, through the American Rescue Plan, a total of USD$472 billion2 for schools as well as state, local, and tribal governments which can be used to deploy systems such as CounterAct UR10 UVC disinfection light fixtures.

“With our latest addition to the Christie CounterAct line of UVC disinfection fixtures, we are excited to continue to help organizations create greater confidence in indoor spaces as we return to in person interaction,” said Brent Peckover, director, industrial applications, Christie. “The high-power upper room ultra-violet germicidal irradiation (UVGI) disinfection performance of UR10, combined with visible light capabilities to light your space, allows businesses to replace existing commercial light fixtures as a cost-effective solution.”

CounterAct UR10, which kills both airborne and surface pathogens, can be installed in rooms with ceiling heights between 9 and 22 feet (3-7.6m), includes remote control features with iOS and Android support, and can be integrated with building automation/management systems. Peckover explains, “UVC disinfection systems should be seamless and require no day-to-day user interaction while effectively inactivating pathogens in the occupied space.”

______________________________________________

1 “Visualizing the History of Pandemics,” Visual Capitalist, March 14, 2020.

2 “Fact Sheet: Biden Administration Launches Effort to Improve Ventilation and Reduce the Spread of COVID-19 in Buildings,” The White House Briefing Room, March 17, 2022

Notes:

*All references to “disinfect”, “disinfecting” and “disinfection” refer generally to the reduction of pathogenic bioburden and are not intended to refer to any specific definition as may be used by any governmental or regulatory authority including the U.S. Food and Drug Administration and the U.S. Environmental Protection Agency.

The pathogen-reducing efficacy of Christie CounterAct products and their use in occupied spaces is dependent on many site-specific factors as well as proper installation and operation within specifications and in accordance with American Conference of Governmental Institutional Hygienist (ACGIH) guidelines.

Ushio’s Care222® filtered Far UV-C technology (“Care222 Technology”) is protected under U.S. and non-U.S. patents. Christie has filed one or more patent application(s) related to technical innovations in the Christie CounterAct UR10.

Share article on social media or email:

Travel with a woman on a journey of emotions and passions that ultimately lead to happiness and joy


News Image

The spirit of the daughter she lost wants Lilibet Rain to be happy above all else. Over the last 10 years, focusing on self-improvement, a positive attitude and working closely with nature, it helped her achieve that state. Now, she wanted to help other people as well who have gone through loss, particularly losing a child, to heal and have a happy life. It is for this reason she writes “Growing Happiness: Turning Loss and Grief into Joy” (published by Balboa Press).

Rain lost her home and possessions, her 24-year-old daughter and her 18-year marriage. If that was not enough, she also went through dramatic health challenges: surviving cancer and learning to live with a heart condition. Yet she is one of the most passionate and happy people one can meet. She made a decision along the way not to be a victim of life, and instead to be a hero. She embraced forgiveness as a key to living a happy life. Her passions for teaching and organic farming have been both her therapy and her driving force to happiness.

“Depression and suicide are on the rise amongst people who have suffered major loss. They find it difficult to heal and find happiness again in their lives. This was made much worse due to the pandemic, where many people lost loved ones prematurely due to contracting COVID-19. It is a time where healing from loss is needed more than ever before. It is also a time when people have become disconnected from nature and are suffering from ‘Nature Deficit disorder,’ Rain says. She adds, “The book gives hope to readers that despite any losses they have gone through in life, they can find happiness and live a fulfilled life. It is both a story and a transformational book and will appeal to both those who enjoy fiction/stories and non-fiction/self-improvement.”

When asked what she wants readers to take away from the book, Rain answers, “I would like my readers to feel inspired to spend time in nature and embrace the inner tools of acceptance, forgiveness and gratitude so that they can heal and have a happy life. Happiness is a choice we make, a choice to connect to the truth of our souls instead of to the false, exterior world. My greatest wish for them is that they make a lasting commitment to be happy. The prize will surely be a magical, joyful life beyond their wildest dreams.” For more details about the book, please visit https://www.balboapress.com/en/bookstore/bookdetails/821952-growing-happiness

“Growing Happiness: Turning Loss and Grief into Joy”

By Lilibet Rain

Hardcover | 6 x 9in | 150 pages | ISBN 9798765232262

Softcover | 6 x 9in | 150 pages | ISBN 9798765232248

E-Book | 150 pages | ISBN 9798765232255

Available at Amazon and Barnes & Noble

About the Author

Lilibet Rain is a teacher, writer, artist, home economist, environmentalist, farmer and an entrepreneurial businesswoman. She was awarded Social Entrepreneur of the Year in 2015 by the Women in Business Association in Botswana. She has written over 20 home economics and art textbooks. She continues to write regular articles on organic gardening in local magazines and now contributes to a digital magazine. Thus, she is no stranger to writing but this will be her first transformational book with more to come.

Balboa Press, a division of Hay House, Inc. – a leading provider in publishing products that specialize in self-help and the mind, body, and spirit genres. Through an alliance with the worldwide self-publishing leader Author Solutions, LLC, authors benefit from the leadership of Hay House Publishing and the speed-to-market advantages of the self-publishing model. For more information, visit balboapress.com. To start publishing your book with Balboa Press, call 844-682-1282 today.

Share article on social media or email:

Trident University International Names Dr. Patricia Rhynders Dean of College of Health and Human Services


Dr. Patricia Rhynders, Dean, Trident’s College of Health and Human Services

With nearly two decades of service to Trident and a stellar record as an administrator and educator, I expect Dr. Rhynders to thrive as Dean of our College of Health and Human Services. – Dr. Conna Bral, Vice Provost, Trident

Dr. Patricia Rhynders has been named Dean of Trident University International’s (Trident) College of Health and Human Services (CHHS).

As Dean, Dr. Rhynders will be responsible for strengthening the University’s commitment to academic excellence and positive student experiences in CHHS programs. These initiatives include expansion and continued quality and rigor of the college’s programs in public health, health administration, and homeland security.

Since joining Trident in 2004, Dr. Rhynders has held multiple roles, including Associate Dean, Program Director, Faculty Lead, and Associate Professor.

“With nearly two decades of service to Trident and a stellar record as an administrator and educator, I expect Dr. Rhynders to thrive as Dean of our College of Health and Human Services,” remarks Dr. Conna Bral, Vice Provost, Trident. “Her expertise, passion, and drive continue to make a positive impact on both her students and colleagues.”

Dr. Rhynders is a master-certified health education specialist (MCHES) with more than 30 years of experience developing and directing health promotion programs in community, nonprofit, hospital, and academic settings. She has extensive experience creating, teaching, and assessing e-learning curricula.

Dr. Rhynders holds a Ph.D. in Health Studies and Higher Education from Texas Woman’s University; a Master’s in Public Health in Community Health Education from California State University, Long Beach; and a Bachelor’s in Community Health Education from SUNY College, Brockport.

About Trident University International

Founded in 1998, Trident University International is a member of the American InterContinental University System, which is accredited by the Higher Learning Commission (hlcommission.org). Trident uses the EdActive™ learning approach, which employs case-based learning in an online setting to teach real-world relevant critical thinking skills designed to enhance the lives and education of students. Trident offers quality associate, bachelor’s, master’s, and doctoral degree programs and certificates, led by a qualified faculty team, over 80% of whom have doctoral degrees. Trident has over 32,000 alumni, of which more than 27,000 have a military affiliation, and has received acknowledgements from Washington Monthly, Military Times, and Military Advanced Education & Transition for their dedication to student success. Visit http://www.trident.edu or call at (855) 290-0290 to learn more about Trident’s wide range of educational options.

Share article on social media or email: